Patrice Lee's HRT menopause story gets the basics right

What did @iampatricelee actually say?

Patrice Lee describes being thrown into surgical menopause in her early 40s after both ovaries were removed following two hysterectomy-adjacent procedures. She tried transdermal cream and patches before settling on oral estradiol 1mg, which she says "settled me down enough" to function. She's now past 60 and still on the same dose with her doctor's blessing, based on clean labs. She frames HRT not as a cure but as a stabilizer: "it wasn't a magic pill."

Her account is personal and experiential, not prescriptive. She's clear that some women can't take HRT due to family history or health reasons, and she doesn't push a specific brand, dose, or protocol. The "secret" she teases is simply that she's still on estradiol after 60, which her doctor approved based on her lab results. Straightforward stuff, honestly.

Does the science back this up?

Yes, mostly. The evidence for HRT in surgically menopausal women is actually stronger than for natural menopause, and the risk calculus looks different. Her experience tracks with what researchers have found.

Surgical menopause, meaning bilateral oophorectomy before natural menopause, produces an abrupt estrogen withdrawal that's metabolically more disruptive than the gradual decline of natural menopause. The SWAN study (Sowers et al., 2008, Journal of Clinical Endocrinology and Metabolism) and follow-up work have consistently shown faster bone density loss and more severe vasomotor symptoms in this population. Estrogen therapy is considered standard of care for women under 45 who undergo bilateral oophorectomy, per the Menopause Society (formerly NAMS).

As for continuing past 60: the 2022 updated position statement from the Menopause Society explicitly dropped arbitrary age cutoffs for HRT discontinuation. Duration decisions are now individualized based on symptom burden, risk factors, and ongoing benefit assessment, exactly what Patrice's doctor did. The Women's Health Initiative (WHI) data, once used to scare women off HRT entirely, has been substantially reinterpreted. The harm signals were concentrated in older women starting HRT years after menopause, not in younger women starting near menopause onset (Manson et al., 2013, JAMA Internal Medicine).

What did they get wrong (or right)?

She got the core narrative right. But there are a few things worth flagging, not because she's being dishonest, but because her framing could leave gaps for viewers self-navigating this decision.

First, she doesn't mention progesterone. Women who have had their uterus removed don't need progestogen, which is actually a point in their favor from a risk perspective. The WHI's elevated breast cancer signal was in the combined estrogen-progestin arm (CEE + MPA), not the estrogen-only arm (Anderson et al., 2012, Lancet Oncology). Patrice's situation as a hysterectomized woman on estrogen-only therapy is actually among the lower-risk HRT profiles. She doesn't say this, and her audience might not know it.

Second, she mentions trying cream and patches before tablets. Oral estradiol has a first-pass liver effect that transdermal routes avoid, and some evidence suggests transdermal delivery carries a lower venous thromboembolism risk (Canonico et al., 2007, Circulation). The fact that she couldn't tolerate patches due to skin reactions is a real clinical barrier, and her outcome on oral estradiol has clearly been fine, but viewers shouldn't assume oral is always the preferred route.

Third, the framing around labs being "absolutely amazing" is vague. What labs? Estrogen levels? Lipids? DEXA scan? For women on long-term estradiol past 60, monitoring should include cardiovascular markers and bone density. That nuance is missing.

What should you actually know?

The biggest takeaway here is that Patrice's situation, surgical menopause from bilateral oophorectomy, has different clinical considerations than natural menopause. Don't one-to-one map her experience to yours without accounting for that difference.

For women with surgical menopause before 45, estrogen replacement isn't just symptom management. It's potentially protective against cardiovascular disease and osteoporosis. The Nurses' Health Study (Colditz et al., 1994, NEJM) and more recent cohort data suggest that women who undergo early oophorectomy without estrogen therapy face elevated risks for cardiovascular events and cognitive decline. The case for treating this group is stronger than for natural menopause cohorts.

For women approaching or past 60 who are considering continuing HRT: the conversation should be individualized. The Menopause Society's 2022 guidance says there is no mandatory stopping point. But cardiovascular risk, breast cancer history, and personal symptom burden all factor in. "As long as your labs and everything is good" is a reasonable clinical approach, but specificity matters. Push your doctor to explain which markers they're tracking and why.

HRT is not a monolith. Oral versus transdermal, estrogen-only versus combined, dose and formulation all affect the risk-benefit profile differently. Patrice's account is honest about her path, but your path may look quite different.